NCT05256732View on ClinicalTrials.gov

Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal

PHASE1CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

August 23, 2022

Study Completion Date

August 23, 2022

Conditions
Healthy Volunteer Study
Interventions
DRUG

AT-527 fasted

AT-527 administered twice daily (BID) for 5 days fasted

OTHER

Placebo Comparator fasted

Matching placebo administered twice daily (BID) for 5 days fasted

DRUG

AT-527 fed

AT-527 administered twice daily (BID) for 5 days fed

OTHER

Placebo Comparator fed

Matching placebo administered twice daily (BID) for 5 days fed

DRUG

AT-527

AT-527 administered twice daily (BID)

DRUG

AT-527 single dose

AT-527 single dose fasted/fed cross-over

Trial Locations (1)

Unknown

Atea Study Site, Québec

Sponsors
All Listed Sponsors
lead

Atea Pharmaceuticals, Inc.

INDUSTRY

NCT05256732 - Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal | Biotech Hunter | Biotech Hunter